Pharmafile Logo
Pharmafocus logo
Advanced Search

Novartis signs agreement to manufacture CureVac’s COVID-19 vaccine

March 5, 2021
Medical Communications COVID-19, CureVac, Novartis, vaccines

CureVac and Novartis have signed an initial agreement for the manufacturing of CureVac’s COVID-19 vaccine candidate, CVnCoV. Preparations for the …

News
houses_of_parliament_london_7654658782

UK government invests £5m in COVID-19 mRNA vaccine library

March 5, 2021
Medical Communications COVID-19, CPI, government, vaccines

The Centre for Process Innovation (CPI) has received a £5 million investment from the UK government, to support the development …

News
Takeda building

Takeda agree $856m deal with Ovid to take over soticlestat development

March 4, 2021
Ovid, Takeda, epilepsy treatment, epiplepsy, soticlestat

Ovid Therapeutics and Takeda have agreed a deal worth up to $856 million, allowing the latter to take over development …

News

Beyond Batten Disease Foundation partners with Actelion on development of combination treatment

March 4, 2021
Actelion, Batten disease, Janssen

Beyond Batten Disease Foundation (BBDF) has partnered with Actelion Pharmaceuticals, a Janssen company, to provide Zavesca (miglustat) for the development of …

News
a vaccine is administered

Bharat Biotech’s COVAXIN jab 81% effective in Phase III trial

March 4, 2021
Bharat Biotech, COVID-19, COVID-19 vaccine, Vaccine, bharat

Bharat Biotech’s COVID-19 vaccine candidate has shown an interim efficacy of 81% in a Phase III trial, the company announced …

News

Hong Kong Baptist University researchers develop drug for EBV-associated cancers

March 4, 2021
Cancer, Epstein-barr virus, Hong Kong

Researchers at Hong Kong Baptist University have developed a novel drug with the potential to become a next-generation treatment for …

News

ConserV and eTheRNA partner on infectious disease vaccines

March 4, 2021
ConserV, eTheRNA, vaccines

ConserV Bioscience and eTheRNA immunotherapies have agreed to collaborate on the development of vaccine candidates for infectious diseases. ConserV is …

News
COVID-19 virus

Pharmafile.com’s weekly COVID-19 news round-up

March 3, 2021
Research and Development

The past week has continued to see positive COVID-19 news; COVAX has delivered their first batch of vaccines to Africa, …

News

ViaCyte and Gore collaborate on new diabetes treatments

March 3, 2021
Research and Development Type 1 diabetes, diabetes, diabetes treatment, gore, viacyte

Clinical stage medicine company ViaCyte have extended their collaboration with materials science organisation Gore to develop new candidates for the …

News
abbvie

AbbVie funds Mitokinin’s Parkinson’s research with option to buy

March 3, 2021
Research and Development AbbVie, Mitokinin, Parkinson's

AbbVie has landed an option to buy neurodegenerative disease-focused biotech Mitokinin following completion of investigational new drug (IND)-enabling studies on …

News
mavenclad

NHS England increases access to cladribine tablets for multiple sclerosis patients during pandemic

March 3, 2021
Research and Development Cladribine, Mavenclad, Merck, multiple sclerosis

NHS England has updated the Blueteq requirements for patients with highly active relapsing MS starting Merck’s cladribine (Mavenclad) tablets during …

News
astrazeneca_plaque

AstraZeneca wins US court ruling on Symbicort patent claims

March 3, 2021
Research and Development AstraZeneca, Symbicort, law

A US district court has ruled in favour of AstraZeneca in litigation against Mylan Pharmaceuticals and Kindeva Drug Delivery, AstraZeneca …

News

Verona Pharma appoints Novartis Gene Therapies VP Lisa Deschamps to its board

March 2, 2021
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, verona, verona pharma

Verona Pharma has appointed Lisa Deschamps, Senior Vice President and Chief Business Officer of Novartis Gene Therapies, as Non-Executive Director …

Appointment

SERB acquires BTG to expand its treatment portfolio for unmet medical needs

March 2, 2021
Manufacturing and Production BTG, SERB, specialty pharmaceuticals

SERB Specialty Pharmaceuticals has purchased BTG Specialty Pharmaceuticals, a division of Boston Scientific that develops treatments with critical conditions, for …

News

Single Pfizer or AstraZeneca vaccine dose drastically reduces COVID-19 hospitalisations in over-80s

March 2, 2021
Manufacturing and Production AstraZeneca, COVID-19, COVID-19 vaccine, Pfizer, Vaccine

A single dose of the Oxford-AstraZeneca or the Pfizer-BioNTech vaccine reduces UK hospitalisations in over-80s by 80%, a Public Health …

News
sophie_biguenet_cmo_abivax

Abivax appoints Dr Sophie Biguenet as Chief Medical Officer

March 2, 2021
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Clinical-stage biotechnology company Abivax has appointed Dr Sophie Biguenet as Chief Medical Officer. Dr Biguenet brings 25 years of experience …

Appointment

Cancer Research UK joins forces with Teon to develop new cancer drug

March 2, 2021
Manufacturing and Production Cancer, Cancer Research UK, Teon

Cancer Research UK and Teon Therapeutics have entered a collaboration agreement to progress the early phase clinical development of Teon’s new cancer drug. The partnership …

News

CN Bio receives UK government grant to develop single and multi-organ models for COVID-19 research

March 2, 2021
Manufacturing and Production CN Bio, COVID-19

CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), has received a grant from innovation agency Innovate …

News

Iktos and Pfizer collaborate on AI drug design

March 2, 2021
Manufacturing and Production AI, Iktos, Pfizer

Iktos has announced that its artificial intelligence (AI) technology for de novo design will be applied to selected Pfizer small-molecule …

News
Merck building

Merck and Debiopharm agree €898m deal to develop head and neck cancer treatments

March 1, 2021
Sales and Marketing Debiopharm, Merck, cancer treatment, head and neck cancer, xevinapant

German science and technology company Merck have agreed a worldwide in-licensing agreement with Debiopharm for the development and commercialisation of …

News
The Gateway to Local Adoption Series

Latest content

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026

PSI appoints David Allen as Country Manager for Canada

January 22, 2026

Qureight appoints Steven Bishop as Chief Medical Officer

January 21, 2026

Pierre Fabre Laboratories and Iktos announce oncology collaboration

January 21, 2026

Qureight appoints Rebecca Simmons as Chief Operating Officer

January 20, 2026